Toutes les photos(1)

Documents

B7273

Bezafibrate

Name: Bezafibrate
Brand: SIGMA

≥98%, solid

Synonyme(s) :

2-[4-[2-(4-Chlorobenzamido)ethyl]phenoxy]-2-methylpropanoic acid

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme

Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):

C₁₉H₂₀ClNO₄

Numéro CAS:

41859-67-0

Poids moléculaire :

361.82

Numéro CE :

255-567-9

Numéro MDL:

MFCD00078970

Code UNSPSC :

12352200

ID de substance PubChem :

24891983

Nomenclature NACRES :

NA.77

Pureté

≥98%

Forme

solid

Solubilité

DMF: soluble
deionized water: insoluble
methanol: soluble

Auteur

Roche

Chaîne SMILES

CC(C)(Oc1ccc(CCNC(=O)c2ccc(Cl)cc2)cc1)C(O)=O

InChI

1S/C19H20ClNO4/c1-19(2,18(23)24)25-16-9-3-13(4-10-16)11-12-21-17(22)14-5-7-15(20)8-6-14/h3-10H,11-12H2,1-2H3,(H,21,22)(H,23,24)

Clé InChI

IIBYAHWJQTYFKB-UHFFFAOYSA-N

Informations sur le gène

human ... HBA2(3040) , PPARA(5465) , PPARD(5467) , PPARG(5468)
mouse ... Ppara(19013) , Ppard(19015) , Pparg(19016)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Application

Bezafibrate has been used:

a supplement in the standard diet (SD) for mice to study its effect on diabetes
to evaluate its effect on hepatitis C virus (HCV) assembly and secretion
to evaluate its effect on gonadal steroidogenesis and spermatogenesis of zebrafish and also used as standard for HPLC

Actions biochimiques/physiologiques

Bezafibrate has the ability to repress HCV assembly and secretion. It is used to treat dyslipidemia.

The peroxisome proliferator-activated receptor (PPAR) is a member of the steroid nuclear receptor superfamily. Bezafibrate is a peroxisome proliferator-activated receptor agonist for PPARα, PPARδ, and PPARγ. Lipoprotein lipase (LPL) activator.
PPARgamma agonists, including Bezafibrate, have beneficial effects in the suppression of the inflammatory response during RSV infection and therefore might have clinical efficacy in the course of severe RSV-infection.

Caractéristiques et avantages

This compound is a featured product for Gene Regulation research. Click here to discover more featured Gene Regulation products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

This compound was developed by Roche. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pictogrammes

GHS07

Mention d'avertissement

Warning

Mentions de danger

H302

Classification des risques

Acute Tox. 4 Oral

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 1

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Équipement de protection individuelle

dust mask type N95 (US), Eyeshields, Gloves

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Square-wave voltammetric determination of bezafibrate in pharmaceutical formulations using a cathodically pretreated boron-doped diamond electrode.

Jorge Armando Ardila et al.

Talanta, 103, 201-206 (2012-12-04)

The determination of bezafibrate (BZF) using square-wave voltammetry (SWV) and a cathodically pretreated boron-doped diamond electrode is proposed. Cyclic voltammetry results showed one irreversible oxidation peak for BZF at 1.20 V (vs. Ag/AgCl (3.0 mol L(-1) KCl)) in a 0.04

Bezafibrate ameliorates diabetes via reduced steatosis and improved hepatic insulin sensitivity in diabetic TallyHo mice

Franko A, et al.

Molecular Metabolism, 6(3), 256-266 (2017)

Bezafibrate for X-linked adrenoleukodystrophy.

Marc Engelen et al.

PloS one, 7(7), e41013-e41013 (2012-08-23)

X-linked adrenoleukodystrophy (X-ALD) is caused by mutations in the ABCD1 gene and is characterized by impaired beta-oxidation of very-long-chain fatty acids (VLCFA) and subsequent VLCFA accumulation in tissues. In adulthood X-ALD most commonly manifests as a gradually progressive myelopathy, (adrenomyeloneuropathy;

Simvastatin but not bezafibrate decreases plasma lipoprotein-associated phospholipase A₂ mass in type 2 diabetes mellitus: relevance of high sensitive C-reactive protein, lipoprotein profile and low-density lipoprotein (LDL) electronegativity.

Alexander Constantinides et al.

European journal of internal medicine, 23(7), 633-638 (2012-08-21)

Plasma lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) levels predict incident cardiovascular disease, impacting Lp-PLA(2) as an emerging therapeutic target. We determined Lp-PLA(2) responses to statin and fibrate administration in type 2 diabetes mellitus, and assessed relationships of changes in Lp-PLA(2) with subclinical

Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid.

Akira Honda et al.

Hepatology (Baltimore, Md.), 57(5), 1931-1941 (2012-08-23)

Bezafibrate is a widely used hypolipidemic agent and is known as a ligand of the peroxisome proliferator-activated receptors (PPARs). Recently this agent has come to be recognized as a potential anticholestatic medicine for the treatment of primary biliary cirrhosis (PBC)

Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique